These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 21128693)

  • 1. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
    Gold R
    CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral treatment for multiple sclerosis.
    Killestein J; Rudick RA; Polman CH
    Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging oral drugs for multiple sclerosis.
    Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
    Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
    Thomas RH; Wakefield RA
    Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral treatments in multiple sclerosis].
    Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
    Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognizing and overcoming potential barriers to oral medications for MS.
    Moses H
    J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
    Lu E; Wang BW; Alwan S; Synnes A; Dahlgren L; Sadovnick AD; Tremlett H
    CNS Drugs; 2014 Feb; 28(2):89-94. PubMed ID: 24343726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs: An injection of hope.
    Graham-Rowe D
    Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
    [No Abstract]   [Full Text] [Related]  

  • 9. New oral drugs for multiple sclerosis.
    Gasperini C; Ruggieri S
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of multiple sclerosis therapy.
    Kieseier BC; Wiendl H; Hartung HP; Stüve O
    Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Emerging therapies for multiple sclerosis].
    de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
    Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies in relapsing-remitting multiple sclerosis.
    Marriott JJ; O'Connor PW
    Rev Recent Clin Trials; 2010 Sep; 5(3):179-88. PubMed ID: 20500147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
    English C; Aloi JJ
    Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
    di Nuzzo L; Orlando R; Nasca C; Nicoletti F
    Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel oral agents for multiple sclerosis.
    Burton JM; O'Connor P
    Curr Neurol Neurosci Rep; 2007 May; 7(3):223-30. PubMed ID: 17488588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.